Bradley Peterson, MD, discusses when pediatricians should consider adding a second treatment for pediatric anxiety and why improvement may continue well beyond the first 3 months of therapy.
|Videos|September 22, 2021
Candice Jones, MD, discusses her new book, "High Five Discipline: Positive Parenting for Happy, Healthy, Well-Behaved Kids"
Author(s)Lois Levine, MA
Recently, I talked to Contemporary Pediatrics' Editorial Advisory Board member Candice W. Jones, MD, FAAP, about her new book, "High Five Discipline: Positive Parenting for Happy, Healthy, Well-Behaved Kids," published by the American Academy of Pediatrics.
Advertisement
Advertisement
Related to this article
Bradley Peterson, MD, discusses how treatment preferences, access, tolerability, and patient characteristics can guide pediatric anxiety care when CBT and medication provide similar overall benefits.
CBT and fluoxetine both reduced pediatric anxiety, while starting with CBT before adding medication showed advantages on several outcomes.
FDA approves oral ALK2 inhibitor zilurgisertib for FOP in patients 12+, based on phase 2 PROGRESS data on new heterotopic ossification volume.
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
Starting HPV vaccination earlier gives pediatricians more opportunities to protect children
3
FAQ: How should pediatricians hand off teens with diabetes?
4
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
5